Although Evolent has had discussions with private equity firms about securing financial backing for the transaction, Evolent may not seal the deal, as other companies have shown interest in Advisory Board, according to the report.
The people familiar with the matter told Reuters that Advisory Board has received preliminary offers and will continue talks with bidders in the coming weeks.
It also isn’t clear what form the transaction will take. Sources told Reuters the deal could involve the sale of Advisory Board’s entire company or just divestment of its healthcare arm.
In January, Advisory Board said it planned to cut about 220 jobs, or 5.7 percent of its total workforce. In February, the company said it was exploring potential strategic options.
More articles on healthcare industry transactions:
Bankrupt North Philadelphia Health System gets approval to sell shuttered hospital
Beth Israel, Lahey CEOs: Merger will act as ‘antidote’ to high healthcare costs
Lifespan, Dana-Farber to team up on cancer care
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.